148 related articles for article (PubMed ID: 22095793)
41. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol.
Heard K; Green JL; Bailey JE; Bogdan GM; Dart RC
Aliment Pharmacol Ther; 2007 Jul; 26(2):283-90. PubMed ID: 17593074
[TBL] [Abstract][Full Text] [Related]
42. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation.
Tandon P; Goodman KJ; Ma MM; Wong WW; Mason AL; Meeberg G; Bergsten D; Carbonneau M; Bain VG
Am J Gastroenterol; 2009 Jul; 104(7):1700-6. PubMed ID: 19471253
[TBL] [Abstract][Full Text] [Related]
43. Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function.
Lucey MR; Connor JT; Boyer TD; Henderson JM; Rikkers LF;
Am J Gastroenterol; 2008 Jul; 103(7):1698-706. PubMed ID: 18494835
[TBL] [Abstract][Full Text] [Related]
44. Topiramate as add-on therapy in non-respondent alcohol dependant patients: a 12 month follow-up study.
Fernandez Miranda JJ; Marina González PA; Montes Pérez M; Díaz González T; Gutierrez Cienfuegos E; Antuña Díaz MJ; Bobes García J
Actas Esp Psiquiatr; 2007; 35(4):236-42. PubMed ID: 17592785
[TBL] [Abstract][Full Text] [Related]
45. Does participation in an alcohol administration study increase risk for excessive drinking?
Pratt WM; Davidson D
Alcohol; 2005 Nov; 37(3):135-41. PubMed ID: 16713501
[TBL] [Abstract][Full Text] [Related]
46. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis.
Higuera-de la Tijera F; Servín-Caamaño AI; Serralde-Zúñiga AE; Cruz-Herrera J; Pérez-Torres E; Abdo-Francis JM; Salas-Gordillo F; Pérez-Hernández JL
World J Gastroenterol; 2015 Apr; 21(16):4975-85. PubMed ID: 25945012
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME
Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071
[TBL] [Abstract][Full Text] [Related]
48. Long-term ethanol administration enhances age-dependent modulation of redox state in central and peripheral organs of rat: protection by metadoxine.
Calabrese V; Randazzo G; Ragusa N; Rizza V
Drugs Exp Clin Res; 1998; 24(2):85-91. PubMed ID: 9675549
[TBL] [Abstract][Full Text] [Related]
49. A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence.
De Sousa A; De Sousa A
Alcohol Alcohol; 2004; 39(6):528-31. PubMed ID: 15525790
[TBL] [Abstract][Full Text] [Related]
50. [Effect of body iron stores in the indicators of alcohol abuse and alcoholic liver injury].
Cylwik B; Daniluk M; Chrostek L; Szmitkowski M
Pol Merkur Lekarski; 2010 Jun; 28(168):450-3. PubMed ID: 20642102
[TBL] [Abstract][Full Text] [Related]
51. Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy.
Borro P; Leone S; Testino G
Curr Drug Targets; 2016; 17(2):239-51. PubMed ID: 25981604
[TBL] [Abstract][Full Text] [Related]
52. Severity of alcohol dependence in decompensated alcoholic liver disease: comparison with heavy drinkers without liver disease and relationship to family drinking history.
Gleeson D; Jones JS; McFarlane E; Francis R; Gellion C; Bradley MP; Peck RJ
Alcohol Alcohol; 2009; 44(4):392-7. PubMed ID: 19286679
[TBL] [Abstract][Full Text] [Related]
53. [Metadoxine in the treatment of vomiting in uremic patients under dialysis treatment].
Di Paolo N; De Mia M; Gaggiotti E
Clin Ter; 1984 Aug; 110(3):221-9. PubMed ID: 6237861
[No Abstract] [Full Text] [Related]
54. [Use of remaxol in the combination therapy of post-withdrawal disorders in alcoholic patients with comorbid liver damage].
Bokhan NA; Abolonin AF; Ankudinova IÉ; Kurgak DI; Mandel' AI
Ter Arkh; 2012; 84(10):51-5. PubMed ID: 23227501
[TBL] [Abstract][Full Text] [Related]
55. Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture.
Gutiérrez-Ruiz MC; Bucio L; Correa A; Souza V; Hernández E; Gómez-Quiroz LE; Kershenobich D
Pharmacol Res; 2001 Nov; 44(5):431-6. PubMed ID: 11712874
[TBL] [Abstract][Full Text] [Related]
56. Treatment of alcoholic fatty liver: is the metabolic effect of metadoxine the only reason for improved liver function?
Stefanini GF; Addolorato G; Caputo F; Bernardi M; Gasbarrini G
J Hepatol; 1999 Apr; 30(4):739-40. PubMed ID: 10207820
[No Abstract] [Full Text] [Related]
57. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome.
Krampe H; Stawicki S; Wagner T; Bartels C; Aust C; Rüther E; Poser W; Ehrenreich H
Alcohol Clin Exp Res; 2006 Jan; 30(1):86-95. PubMed ID: 16433735
[TBL] [Abstract][Full Text] [Related]
58. Different drinking patterns for women and men with alcohol dependence with and without alcoholic cirrhosis.
Stokkeland K; Hilm G; Spak F; Franck J; Hultcrantz R
Alcohol Alcohol; 2008; 43(1):39-45. PubMed ID: 17942440
[TBL] [Abstract][Full Text] [Related]
59. Metadoxine (pyrrolidone carboxylate of pyridoxine) antagonizes the locomotor-stimulatory effect of ethanol in mice.
Garau B; Fadda F; Melis F; Gelso E; Gessa GL
Alcohol Alcohol; 1992 Sep; 27(5):501-4. PubMed ID: 1476554
[TBL] [Abstract][Full Text] [Related]
60. Acute alcohol intoxication.
Vonghia L; Leggio L; Ferrulli A; Bertini M; Gasbarrini G; Addolorato G;
Eur J Intern Med; 2008 Dec; 19(8):561-7. PubMed ID: 19046719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
